Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILDR and PD-1/PD-L1 Inhibitors for Metastatic Solid Tumors
NCT06076135Phase 2Completed
- Start
- Dec 2023
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in malignant solid tumor. Primary endpoints: Objective Response Rate at 24 weeks, Disease Control Rate at 24 weeks and 2 more. Started Dec 2023; status: completed.
02
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06076135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06076135.